



(51) International Patent Classification:

A61K 33/06 (2006.01) A61K 31/7016 (2006.01)
A61K 31/192 (2006.01) A61K 31/437 (2006.01)
A61K 31/198 (2006.01) A61P 43/00 (2006.01)
A61K 31/195 (2006.01) A61P 1/10 (2006.01)
A61K 31/7004 (2006.01)

(21) International Application Number:

PCT/US2015/062223

(22) International Filing Date:

23 November 2015 (23.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/083,814 24 November 2014 (24.11.2014) US

(71) Applicant: UCL BUSINESS PLC [GB/GB]; The Network Building, 97 Tottenham Court Road, London W1T 4 TP (GB).

(71) Applicant (for GM only): LIU, Jing [US/US]; 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(72) Inventor: JALAN, Rajiv; The Network Building, 97 Tottenham Court Road, London W1T 4 TP (GB).

(74) Agent: DELANEY, Karoline, A.; KNOBBE MARTENS OLSON & BEAR, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES

FIG. 5A



(57) Abstract: Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (HSCs), such as non-alcoholic fatty liver disease (NAFLD), fibrosis, and liver cancer, using ammonia-lowering therapies.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*